NasdaqCM - Nasdaq Real Time Price USD

OSR Holdings, Inc. (OSRH)

1.2500

0.0000

(0.00%)

At close: 4:00:00 PM EDT

1.2500

0.00

(0.00%)

After hours: 5:55:56 PM EDT

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference, taking place May 2–6, 2025, at the University of Pennsylvania in Philadelphia.

PR Newswire 10 days ago

OSRH
0.00%

OSRHW
Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market.

PR Newswire last month

OSRH
0.00%

OSRHW
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo

PR Newswire last month

OSRH
0.00%

OSRHW
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.

PR Newswire last month

OSRH
0.00%

OSRHW
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.

PR Newswire last month

OSRH
0.00%

OSRHW

Performance Overview

Return	OSRH	S&P 500 (^GSPC)
YTD	-89.16%	-0.64%
1-Year	-88.54%	+11.90%
3-Year	-87.62%	+48.70%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

OSR Holdings, Inc. (OSRH)

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

Performance Overview